ESCRS Homepage

December 2002
IN THIS ISSUE

Transcleral drugs overcome usual delivery limitations
Wavefront rated in 'top five' innovations of last 25 years
Ultrasound tool 'crystal ball' for anterior surgeons
Task force develops classification system for retinopathy screening
Cool laser blasts way to micro-incision cataract surgery
Anterior chamber maintainer adequate for micro surgery
Artemis 2 provides 'unprecedented' diagnostic readings
Laser biometry more reliable with experts and novices
In search of objective accommodation evaluation
Cataract surgery more than meets front of the eye
Combined surgery safe for PEX patients
Deferring PI in filtering surgery does not increase risks
Early glaucoma intervention delays progression
Oxygen may be the culprit in nuclear cataract
New IOL accommodates cataract patients
Trainee surgeons hold didactic wisdom
Antiviral treatment best defence for ocular herpes
Sutureless surgery advances with help of corneal glue
New weapons in the fight against corneal infection
New weapons in the fight against corneal infection
Intravitreal triamcinolone could reduce need for PDT re-treatment in eyes with exudative AMD
Ultra-thin lens reveals mystery accommodation
Two IOL styles prove to be equally accommodating in comparative trial
New drug improves diabetic retinopathy therapy
Good long-term results with combination surgery
Treating ocular cancer with designer molecules
Clear lens extraction prompts vitreoretinal concern
Roots of Fuchs' dystrophy may be found in mitochondrial genes
FEATURES
From The Editor
Reflections on Refractive Surgery
In Your Good Books
Bio-ophthalmology
Beyond The Eye
Regulatory Matters



From The Editors By Clive Peckar FRCS, FRCOphth

IT'S OVER TO YOU: Eutotimes asks for your correspondence

IN this issue we feature an article on the work being carried out by J. William Harbour MD and his colleagues on the development of the HDM2 peptide, a designer compound intended to block a specific metabolic pathway in ocular tumours which would bring about cell death.

The article is typical of the successful evolution of EuroTimes from a publication dealing purely with anterior segment surgery to one now covering the whole spectrum of ophthalmology.

It is our belief that we are well on the way to achieving our aim of producing an interesting monthly news magazine which informs our readers of what is happening in the wide world of ophthalmology.

Above all, this is your publication and while we strive to focus our content on what we feel is the best possible response to readership demand and interest value, we consider your suggestions and feedback vital to our future development.

Next month sees the eighth anniversary of EuroTimes and to mark the success of the magazine, we would like to encourage you to send us any comments or suggestions you may have which we will then publish in a new letters section of the magazine. Tell us what you like and don't like and what new features, sections or commentaries you would like to see.

We will select three outstanding contributions and award the winners free ESCRS membership for one year. If you are already a member you can transfer this membership to a colleague of your choice.

What is important to us is your contribution. The germ of any Society is the collective voice of its members. That is why we encourage each of you to use EuroTimes as a communicative platform for your ideas and opinions.

On behalf of the editorial team, may I wish you a happy and prosperous 2003 and I look forward to hearing from you soon.

Clive Peckar

For more on apoptosis, see the Bio-ophthalmology column in last month's issue of EuroTimes.

Top